39 results found.

Cystic Fibrosis Clinical Trial

National Jewish Health - Recruiting 7 years to 82 years.
- Cystic Fibrosis Nontuberculous Mycobacteria Diagnosis Protocol.

Cystic Fibrosis Clinical Trial using Aztreonam for Inhalation Solution (AZLI); Placebo

Gilead Sciences - Recruiting 6 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis.
Aztreonam for Inhalation Solution (AZLI); Placebo

Lung Diseases Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 9 years to 80 years.
- Clinical Course in Cystic Fibrosis: The Effects of Pseudomonas Aeruginosa and Potential Modifier Genes.

Lung Transplantation, Cystic Fibrosis, or Renal Failure Clinical Trial using Urinary levels of PIIINP and NGAL as a marker of changes in renal function

Nantes University Hospital - Recruiting 18 years or older.
- Predictive Value of PIIINP and Urinary NGAL for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation..
Urinary levels of PIIINP and NGAL as a marker of changes in renal function

Cystic Fibrosis Clinical Trial using Lumacaftor; Lumacaftor Placebo; Ivacaftor; Ivacaftor Placebo; moxifloxacin hydrochloride

Vertex Pharmaceuticals Incorporated - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects.
Lumacaftor; Lumacaftor Placebo; Ivacaftor; Ivacaftor Placebo; moxifloxacin hydrochloride

Cystic Fibrosis Clinical Trial

University Hospitals of Cleveland - Recruiting 18 years to 50 years.
- The Role of IL-17 Neutrophils in CF Lung Inflammation.

Cystic Fibrosis Clinical Trial using CTX-4430; Mannitol; Placebo

Celtaxsys, Inc. - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days.
CTX-4430; Mannitol; Placebo

Fibrosing Colonopathy in Patients With Cystic Fibrosis Clinical Trial using CREON; ZENPEP; ULTRESA; PANCREAZE; other non-sponsor pancreatic enzyme replacement therapy; No pancreatic enzyme replacement therapy

AbbVie - Recruiting N/A or older.
- Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestines Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy).
CREON; ZENPEP; ULTRESA; PANCREAZE; other non-sponsor pancreatic enzyme replacement therapy; No pancreatic enzyme replacement therapy

Cystic Fibrosis Clinical Trial using pancrelipase

AbbVie - Recruiting 2 years or older.
- A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors.
pancrelipase

Cystic Fibrosis Clinical Trial using VX-809; VX-770; VX-809 placebo; VX-770 placebo

Vertex Pharmaceuticals Incorporated - Recruiting 18 years or older.
- A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.
VX-809; VX-770; VX-809 placebo; VX-770 placebo

Cystic Fibrosis Clinical Trial

University of Arkansas - Recruiting 7 years to 17 years.
- Longitudinal Assessment of Fat Free Mass Index and Its Impact on Lung Health and Overall Health Metrics in Pediatric Patients With Cystic Fibrosis.

Cystic Fibrosis Clinical Trial using AquADEKs-2; control multivitamin

University of Colorado, Denver - Recruiting 10 years or older.
- A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients.
AquADEKs-2; control multivitamin

Bronchiectasis Clinical Trial using Ciprofloxacin DPI (BAYQ3939); Placebo

Bayer - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis..
Ciprofloxacin DPI (BAYQ3939); Placebo

Cystic Fibrosis Clinical Trial using Tobramycin Inhalation Powder

Novartis - Recruiting 6 years or older.
- A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis.
Tobramycin Inhalation Powder

Cystic Fibrosis Clinical Trial using Behaviour change intervention

Sheffield Teaching Hospitals NHS Foundation Trust - Recruiting 16 years or older.
- Pilot Study of Behavioural Intervention for Nutrition in Cystic Fibrosis.
Behaviour change intervention

Cystic Fibrosis Clinical Trial

University of Alabama at Birmingham - Recruiting 6 years or older.
- G551D Observational Study (GOAL)-Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2).

Cystic Fibrosis Clinical Trial using ivacaftor

University of California, San Francisco - Recruiting 6 years or older.
- Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients.
ivacaftor

Cystic Fibrosis Related Diabetes, or Cystic Fibrosis Clinical Trial

Children's Hospital of Philadelphia - Recruiting 6 years or older.
- Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis.

Cystic Fibrosis Clinical Trial

Rush University Medical Center - Recruiting 18 years or older.
- Patient Preferences and Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS).

Atypical Mycobacterium Infections, Cystic Fibrosis, or Job's Synd Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections.

Cystic Fibrosis (CF) Clinical Trial using Loestrin (norethindrone acetate and ethinyl estradiol)

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- Gender Disparity and Hormones in Cystic Fibrosis.
Loestrin (norethindrone acetate and ethinyl estradiol)

Bronchiectasis Clinical Trial using Tobramycin

University Medical Centre Groningen - Recruiting 18 years or older.
- Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis.
Tobramycin

Cystic Fibrosis Clinical Trial using Vancomycin inhalation powder; Placebo inhalation powder

Savara Inc. - Recruiting 12 years or older.
- A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients.
Vancomycin inhalation powder; Placebo inhalation powder

Cirrhosis, Liver Fibrosis, Portal Hypertension, Cystic Fibrosis, Clinical Trial using Elastometry

Assistance Publique - H“pitaux de Paris - Recruiting 6 Months to 18 years.
- Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of FIBROSCANN..
Elastometry

Lung; Disease, Cystic Fibrosis, or Healthy Clinical Trial

University of British Columbia - Recruiting 19 years to 50 years.
- Qualitative Descriptors of Dyspnea During Exercise in Cystic Fibrosis.

Cystic Fibrosis Clinical Trial

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Extra Pulmonary Determinants of Physical Activity in Adults With Cystic Fibrosis..

Cystic Fibrosis Clinical Trial using ivacaftor

Vertex Pharmaceuticals Incorporated - Recruiting 6 years or older.
- A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation.
ivacaftor

Cystic Fibrosis Clinical Trial using Physiotherapy, exercise, percutaneous gastrostomy feeds; Anti-reflux pharmacotherapy

Bayside Health - Recruiting 16 years to 70 years.
- The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function.
Physiotherapy, exercise, percutaneous gastrostomy feeds; Anti-reflux pharmacotherapy

Allergic Broncho-Pulmonary Aspergillosis Clinical Trial using Study of predictive factors

Nantes University Hospital - Recruiting 18 years or older.
- Interest of TARC Serum Marker for Follow-up of Patients With Allergic Broncho-Pulmonary Aspergillosis (ABPA), Excluding Cystic Fibrosis.
Study of predictive factors

Cystic Fibrosis Clinical Trial

Yale University - Recruiting 3 Months to 4 years.
- Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis.

Cystic Fibrosis Clinical Trial using Xylitol; Saline

University of Iowa - Recruiting 16 years or older.
- Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis.
Xylitol; Saline

Cystic Fibrosis, or Vitamin D Deficiency Clinical Trial using 5000 IU of cholecalciferol; placebo

St. Michael's Hospital, Toronto - Recruiting 18 years or older.
- Randomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic Fibrosis.
5000 IU of cholecalciferol; placebo

Cystic Fibrosis, Children, Exhaled Breath Condensate, Non-invasiv Clinical Trial using Diagnostic intervention without standard therapy; Diagnostic intervention with standard therapy

Maastricht University Medical Center - Recruiting 5 years to 18 years.
- Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate).
Diagnostic intervention without standard therapy; Diagnostic intervention with standard therapy

Asthma, Cystic Fibrosis, Chronic Lung Disease, or Pneumonia Clinical Trial

Maastricht University Medical Center - Recruiting 6 years to 18 years.
- Optimising and Standardising Measurements of Inflammatory Markers in Exhaled Breath (EB) and Exhaled Breath Condensate (EBC).

Cystic Fibrosis Clinical Trial using Nebcinal Tobi; Tobi Nebcinal

Erempharma - Recruiting 6 years or older.
- Pharmacokinetic Bioequivalence Study of Nebcinalr 150mg/3ml Administered by Aeronebr Idehalerr Versus Tobir 300mg/5ml Administered by Pari LC Plusr.
Nebcinal Tobi; Tobi Nebcinal